<DOC>
	<DOC>NCT01527643</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 in healthy male subjects.</brief_summary>
	<brief_title>Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Considered generally healthy upon completion of medical history and physical examination, as judged by the investigator Body Mass Index (BMI) between 19.030.0 kg/m^2 Glycohemoglobin (HbA1c) within laboratory normal range Nonsmokers The receipt of any investigational drug within the last 3 months prior to this trial. Clinically significant abnormal haematology, biochemistry, urinalysis or ECG (electrocardiogram) screening tests, as judged by the investigator Liver enzyme values (ALAT and ASAT) exceeding 2 times the upper reference limit according to the local laboratory History of or current addiction to alcohol or drugs of abuse as determined by the investigator (positive urine drug screen and breath alcohol screen) HIV (human immunodeficiency virus), Hepatitis B or C positive Subjects with a firstdegree relative with diabetes mellitus A history of multiple and/or severe allergies to drugs or foods or a history of anaphylactic reactions</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>